Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Bauer, Joschka, Mathias, Sven, Kube, Sebastian, Otte, Kerstin, Garidel, Patrick, Gamer, Martin, Blech, Michaela, Fischer, Simon, Karow-Zwick, Anne R
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7531517/
https://ncbi.nlm.nih.gov/pubmed/32658605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1787121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados